Literature DB >> 10180516

Diagnosis and management of pigmentary glaucoma.

I Lehto1, E Vesti.   

Abstract

Pigment dispersion syndrome and pigmentary glaucoma affect typically young, myopic persons. Iridozonular contact causes pigment dispersion and obstruction of the trabecular meshwork. Accumulation of pigment may result in transient elevation of intraocular pressure or irreparable damage to the meshwork accompanied by uncontrolled glaucoma. In the reviewed publications the transition from pigment dispersion syndrome to pigmentary glaucoma was found to be 20%. The main risk factors for the transition were ocular hypertension and myopia. Dapiprazole, an alpha-adrenergic blocking agent, was found to be effective in treating pigmentary glaucoma and in preventing pressure spikes after exercise. Dapiprazole causes miosis without affecting accommodation. Yttrium aluminum garnet laser iridotomy reduced the incidence of ocular hypertension in pigment dispersion syndrome, although the effect was less pronounced in persons older than 40 years of age. Lattice degeneration was found in 33.3% of the eyes with pigment dispersion syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10180516     DOI: 10.1097/00055735-199804000-00012

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

1.  Long-term Efficacy of Trabeculectomy on Chinese Patients with Pigmentary Glaucoma: A Prospective Case Series Observational Study.

Authors:  Guo-Ping Qing; Ning-Li Wang; Tao Wang; Hong Chen; Da-Peng Mou
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

2.  Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature.

Authors:  Elisabeth Wittström
Journal:  Open Ophthalmol J       Date:  2017-05-22

3.  Pigmentary Glaucoma with Retinochoroidal Pigmentation.

Authors:  Syed Shoeb Ahmad; Shuaibah Abdul Ghani
Journal:  J Ophthalmic Vis Res       Date:  2016 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.